New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Radiopharm Theranostics Limited - Sponsored ADR (RADX) P/E ratio

Alert me on P/E ratio

P/E ratio, daily

No history to chart for RADX yet.

Annual newest first

Period P/E ratio Change

P/E ratio against peers

Company P/E ratio
LEXX Lexaria Bioscience Corp. compare n/m
PASG Passage Bio, Inc. compare n/m
BCDA BioCardia, Inc. compare n/m
LSTA Lisata Therapeutics, Inc. compare n/m
AEON AEON Biopharma, Inc. compare n/m
HIND Vyome Holdings, Inc. compare n/m
BIVI BioVie Inc. compare n/m
PBM Psyence Biomedical Ltd. compare 0.1×
RADX Radiopharm Theranostics Limited - Sponsored ADR —
Biotechnology industry median 8.5×
Healthcare sector median 21.7×
Market median 16.6×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on RADX